A randomized trial comparing 5-mg and 10-mg warfarin loading doses.
Open Access
- 11 January 1999
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 159 (1) , 46-48
- https://doi.org/10.1001/archinte.159.1.46
Abstract
ALTHOUGH WARFARIN sodium is an effective antithrombotic agent, it has a narrow therapeutic window and a widely variable dose-response relationship among patients with thromboembolic disorders. An inadequate anticoagulant effect is associated with reduced efficacy,1 and an excessive anticoagulant effect with increased bleeding.2 Consequently, the anticoagulant effect of warfarin has to be monitored carefully and the dose adjusted so that the prothrombin time (PT) is maintained in a safe and effective range. For most thromboembolic disorders, the therapeutic range for the PT is equivalent to an international normalized ratio (INR) of 2.0 to 3.0.3This publication has 5 references indexed in Scilit:
- Antithrombotic Therapy for Venous Thromboembolic DiseaseChest, 1995
- Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.Journal of Clinical Investigation, 1993
- Anticoagulant-related bleeding: Clinical epidemiology, prediction, and preventionThe American Journal of Medicine, 1993
- Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapyThrombosis Research, 1987
- Survival Time of Prothrombin and Factors VII, IX and X after Completely Synthesis Blocking Doses of Coumarin DerivativesBritish Journal of Haematology, 1963